Skip to main content

Table 3 Total efficacy evaluation

From: Short-term survival and safety of apatinib combined with oxaliplatin and S-1 in the conversion therapy of unresectable gastric cancer

Variable

Patients, N (%)

CR

1 (2.7)

PR

26 (70.3)

SD

3 (8.1)

PD

7 (18.9)

ORR

27 (73.0)

DCR

30 (81.1)

Surgical conversion

22 (59.5)

R0 resection

14 (63.6)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us